

MEDIMMUNE INC /DE  
Form 8-K  
November 18, 2003

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D. C. 20549**

**FORM 8-K**

---

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report

November 17, 2003

**MedImmune, Inc.**

**(Exact name of registrant as specified in its charter)**

Delaware  
(State or other jurisdiction of  
incorporation or organization)

000-19131  
(Commission File No.)

52-1555759  
(I.R.S. Employer Identification No.)

35 West Watkins Mill Road, Gaithersburg, MD 20878  
(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (301) 417-0770

---

**Item 9. Regulation FD Disclosure.**

On November 17, 2003, MedImmune, Inc. (the Company) issued a press release announcing revised guidance for the 2003 fourth quarter and full year, and will conduct a publicly available conference call to discuss the revised guidance on November 18, 2003 at 8:00 a.m. Eastern Time. A copy of the Company's press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

This information is being furnished pursuant to Items 9 and 12 of Form 8-K and is being presented under Item 9 of Form 8-K in accordance with interim guidance issued by the Securities and Exchange Commission in Release Nos. 33-8216 and 34-47583. This information is not deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934 and is not incorporated by reference into any registration statements filed under the Securities Act of 1933 or any report filed under the Securities Exchange Act of 1934.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MEDIMMUNE, INC.**

BY: /s/ Lota S. Zoth

Lota S. Zoth  
Vice President and Controller

Dated: November 17, 2003

---

## EXHIBIT INDEX

*Exhibit Description*

99.1	Press release, dated November 17, 2003, MedImmune Provides Update to FluMist Launch and Revises Guidance for 2003 Fourth Quarter and Full Year
------	--